The recent prospectively designed ADAPTeR study demonstrated that the abundance of clonally expanded CD8+ T cells present in the tumor at diagnosis and their persistence during treatment with anti-PD1 therapy were predictors of response (13). Here, PDCD1 is linked to neoplasm.